Expression of HER2 and MUC1 in Advanced Colorectal Cancer: Frequency and Clinicopathological Characteristics-Reference-Cited by-同舟云学术

Expression of HER2 and MUC1 in Advanced Colorectal Cancer: Frequency and Clinicopathological Characteristics

Published:2013 Issue:2 Volume:25 Page:93-100
ISSN:0915-6380
Container-title:The Showa University Journal of Medical Sciences
language:en
Short-container-title:Showa Univ J Med Sci

Author:

ASONUMA Kunio¹²,DATE Yuko¹,TSUKUDA Genki¹,HIRABAYASHI Kodai¹,WADA Yuusuke¹,TAKAHASHI Hiroshi²,KUNIMURA Toshiaki³,HAMATANI Shigeharu³,MOROHOSHI Toshio¹

Affiliation:

1. Department of Pathology, Showa University School of Medicine

2. Department of Medicine, Division of Gastroenterology, Showa University Fujigaoka Hospital

3. Department of Pathology, Clinico-diagnostic Pathology, Showa University Northern Yokohama Hospital

Publisher

The Showa University Society

Link

https://www.jstage.jst.go.jp/article/sujms/25/2/25_93/_pdf

Reference24 articles.

1. 1) Archer SG, Eliopoulos A, Spandidos D, et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer. 1995;72:1259-1266.

2. 2) Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998;16:413-428.

3. 3) Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.

4. 4) Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697.

5. 5) Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases;Molecular Case Studies;2018-02-08

2. Immunohistochemical Study of HER2/neu Expression in Colorectal Cancer and its Relation to other Clinicopathological Criteria and Prognostic Factors;International Journal of Cancer Management;2017-05-06